Biophysical Underpinnings of the Repeat Length Dependence of Polyglutamine Amyloid Formation*

Background: The molecular basis for the repeat length dependence of disease risk in polyglutamine diseases is not known. Results: We show here a nonlinear dependence of aggregation propensity versus polyglutamine repeat length that qualitatively mirrors how age of onset depends on repeat length. Conclusion: This provides further support for a role for aggregation in these diseases. Significance: This lends support to therapeutic strategies targeting aggregation. There are now 10 expanded CAG repeat diseases in which both disease risk and age of onset are strongly dependent on the repeat length of the polyglutamine (polyQ) sequence in the disease protein. Large, polyQ-rich inclusions in patient brains and in cell and animal models are consistent with the involvement of polyQ aggregation in the disease mechanism. This possibility is reinforced by studies showing strong repeat length dependence to the aggregation process, qualitatively mirroring the repeat length dependence of disease risk. Our understanding of the underlying biophysical principles that mediate the repeat length dependence of aggregation, however, is far from complete. A previous study of simple polyQ peptides showed that N*, the size of the critical nucleus that controls onset of aggregation, decreases from unfavorable tetramer to favorable monomer over the range Q23 to Q26. These data, however, do not explain why, for all peptides exhibiting N* ∼ 1, spontaneous aggregation rates continue to increase with increasing repeat length. Here we describe a novel kinetics analyses that maps out the nonlinear dependence with repeat length of a nucleation efficiency term that is likely related to aspects of nucleus structure. This trend accounts for why nucleus size increases to tetrameric at repeat lengths of Q23 or below. Intriguingly, both aggregation and age of onset trend with repeat length in similar ways, exhibiting large changes per added Gln at low repeat lengths and small changes per added Gln at relatively long repeat lengths. Fibril stability also increases with repeat length in a nonlinear fashion.

[1]  R. Morimoto,et al.  Huntington's disease: underlying molecular mechanisms and emerging concepts. , 2013, Trends in biochemical sciences.

[2]  I. Lednev,et al.  Levels of supramolecular chirality of polyglutamine aggregates revealed by vibrational circular dichroism , 2013, FEBS letters.

[3]  K. Kar,et al.  β-hairpin-mediated nucleation of polyglutamine amyloid formation. , 2013, Journal of molecular biology.

[4]  S. Shaham,et al.  PolyQ disease: misfiring of a developmental cell death program? , 2013, Trends in cell biology.

[5]  Miki Nakano,et al.  Study of the aggregation mechanism of polyglutamine peptides using replica exchange molecular dynamics simulations , 2013, Journal of Molecular Modeling.

[6]  Lucien E. Weiss,et al.  Cellular Inclusion Bodies of Mutant Huntingtin Exon 1 Obscure Small Fibrillar Aggregate Species , 2012, Scientific Reports.

[7]  H. Orr.  Polyglutamine neurodegeneration: expanded glutamines enhance native functions. , 2012, Current opinion in genetics & development.

[8]  D. Rubinsztein,et al.  Autophagy and polyglutamine diseases , 2012, Progress in Neurobiology.

[9]  R. Pappu,et al.  Assessing the contribution of heterogeneous distributions of oligomers to aggregation mechanisms of polyglutamine peptides. , 2011, Biophysical chemistry.

[10]  D. Altschuh,et al.  Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions. , 2011, Human molecular genetics.

[11]  J. Kelly,et al.  Amyloid-β Forms Fibrils by Nucleated Conformational Conversion of Oligomers , 2011, Nature chemical biology.

[12]  Dobrila D. Rudnicki,et al.  An Antisense CAG Repeat Transcript at JPH3 Locus Mediates Expanded Polyglutamine Protein Toxicity in Huntington's Disease-like 2 Mice , 2011, Neuron.

[13]  K. Kar,et al.  Assays for studying nucleated aggregation of polyglutamine proteins. , 2011, Methods.

[14]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[15]  K. Kar,et al.  Critical nucleus size for disease-related polyglutamine aggregation is repeat length dependent , 2010, Nature Structural &Molecular Biology.

[16]  Osamu Onodera,et al.  Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going? , 2010, Journal of molecular cell biology.

[17]  Elena Cattaneo,et al.  Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.

[18]  J. Marsh,et al.  A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis. , 2010, Biophysical journal.

[19]  S. M. Rothstein,et al.  Comparative characterization of short monomeric polyglutamine peptides by replica exchange molecular dynamics simulation. , 2010, The journal of physical chemistry. B.

[20]  Leslie M Thompson,et al.  Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Manner in Vitro and in Vivo* , 2010, The Journal of Biological Chemistry.

[21]  Tuomas P. J. Knowles,et al.  An Analytical Solution to the Kinetics of Breakable Filament Assembly , 2009, Science.

[22]  S. Finkbeiner,et al.  Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease , 2009, Human molecular genetics.

[23]  A. Reiner,et al.  CAG repeat lengths ≥335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse , 2009, Neurobiology of Disease.

[24]  Dalaver H. Anjum,et al.  Polyglutamine disruption of the huntingtin exon1 N-terminus triggers a complex aggregation mechanism , 2009, Nature Structural &Molecular Biology.

[25]  C. Ross,et al.  A Comparison of Huntington Disease and Huntington Disease-Like 2 Neuropathology , 2008, Journal of neuropathology and experimental neurology.

[26]  M. Kinjo,et al.  Detection of Polyglutamine Protein Oligomers in Cells by Fluorescence Correlation Spectroscopy* , 2007, Journal of Biological Chemistry.

[27]  L. Cardon,et al.  The Relationship Between CAG Repeat Length and Age of Onset Differs for Huntington's Disease Patients with Juvenile Onset or Adult Onset , 2007, Annals of human genetics.

[28]  F. Walker.  Huntington's disease , 2007, The Lancet.

[29]  Ronald Wetzel,et al.  Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins , 2006, Proceedings of the National Academy of Sciences.

[30]  Stephen P Bottomley,et al.  The Two-stage Pathway of Ataxin-3 Fibrillogenesis Involves a Polyglutamine-independent Step* , 2006, Journal of Biological Chemistry.

[31]  Ronald Wetzel,et al.  Alanine scanning mutagenesis of Abeta(1-40) amyloid fibril stability. , 2006, Journal of molecular biology.

[32]  Ronald Wetzel,et al.  Oligoproline effects on polyglutamine conformation and aggregation. , 2006, Journal of molecular biology.

[33]  Ronald Wetzel,et al.  Polyglutamine aggregation nucleation: Thermodynamics of a highly unfavorable protein folding reaction , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Wetzel,et al.  Thermodynamics of Aβ(1−40) Amyloid Fibril Elongation† , 2005 .

[35]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[36]  Ronald Wetzel,et al.  Kinetic analysis of beta-amyloid fibril elongation. , 2004, Analytical biochemistry.

[37]  Christine Van Broeckhoven,et al.  Pathogenesis of polyglutamine disorders: aggregation revisited. , 2003, Human molecular genetics.

[38]  G. Bates,et al.  Huntingtin aggregation and toxicity in Huntington's disease , 2003, The Lancet.

[39]  R. Wetzel,et al.  Mutational analysis of the structural organization of polyglutamine aggregates , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Christopher A. Ross,et al.  Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization* , 2002, The Journal of Biological Chemistry.

[41]  Ronald Wetzel,et al.  Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Richard I. Morimoto,et al.  The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Wetzel,et al.  Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. , 2001, Journal of molecular biology.

[44]  James F. Gusella,et al.  Molecular genetics: Unmasking polyglutamine triggers in neurodegenerative disease , 2000, Nature Reviews Neuroscience.

[45]  G P Bates,et al.  Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  C A Ross,et al.  Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. , 1998, Human molecular genetics.

[47]  Hans Lehrach,et al.  Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.

[48]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[49]  R. Richards,et al.  Dynamic mutations: where are they now? , 2012, Advances in experimental medicine and biology.

[50]  L. Jones,et al.  Pathogenic mechanisms in Huntington's disease. , 2011, International review of neurobiology.

[51]  K. Tagawa,et al.  [Polyglutamine diseases]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[52]  R. Wetzel,et al.  Kinetics and thermodynamics of amyloid assembly using a high-performance liquid chromatography-based sedimentation assay. , 2006, Methods in enzymology.

[53]  F. Ferrone,et al.  Analysis of protein aggregation kinetics. , 1999, Methods in enzymology.

[54]  Metse PhI.  [Pathogenic mechanisms]. , 1979, Odontostomatologike proodos.